Pancreatic Cancer Research

ResearcherHarbin Medical UniversityNo recent work listed

Hongchi Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8215-8984; OpenAlex author ID A5089574784. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers

Papers 9

  1. Integrating high-throughput microRNA and mRNA expression data to identify risk mRNA signature for pancreatic cancer prognosis. Co-author DOI 10.1002/jcb.29576↗
  2. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses. Co-author DOI 10.1186/s12964-020-0522-4↗
  3. Analysis of 300 consecutive cases of pancreatic adenocarcinoma in a single-center in China. Last author DOI 10.1016/s1499-3872(16)60066-8↗
  4. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Co-author DOI 10.1016/j.bcp.2014.01.041↗
  5. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. Co-author DOI 10.1371/journal.pone.0037222↗
  6. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0043826↗
  7. [Experimental study of the function of nuclear factor-κB-dependent epithelial to mesenchymal transition in pancreatic cancer cells under hypoxic conditions]. Last author PMID 22883954↗
  8. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Co-author DOI 10.1007/s00280-011-1643-7↗
  9. Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.1371/journal.pone.0023752↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueying Sun · 2 shared papers, 2020 · strength 0.24
  2. Bei Sun · 6 shared papers, 2011–2016 · strength 0.21
  3. Guang Jia · 5 shared papers, 2011–2014 · strength 0.15
  4. Shangha Pan · 5 shared papers, 2011–2014 · strength 0.14
  5. Zhuoxin Cheng · 5 shared papers, 2011–2012 · strength 0.14
  6. Ping Wang · 1 shared paper, 2020 · strength 0.13
  7. Ping Wang · 1 shared paper, 2020 · strength 0.12
  8. Shuangjia Wang · 4 shared papers, 2011–2012 · strength 0.11
  9. Rui Kong · 4 shared papers, 2011–2012 · strength 0.11
  10. Lianxin Liu · 1 shared paper, 2016 · strength 0.06
  11. Yong Ma · 1 shared paper, 2016 · strength 0.06
  12. Han Lin · 1 shared paper, 2016 · strength 0.06
  13. Yongwei Wang · 2 shared papers, 2011–2012 · strength 0.05
  14. Xuewei Bai · 2 shared papers, 2011 · strength 0.05
  15. Dongbo Xue · 2 shared papers, 2011 · strength 0.05
  16. Zengfu Song · 1 shared paper, 2014 · strength 0.04
  17. Yongwei Wang · 1 shared paper, 2014 · strength 0.04
  18. Yilong Li · 1 shared paper, 2014 · strength 0.04
  19. Gang Wang · 1 shared paper, 2012 · strength 0.03
  20. Yongwei Wang · 1 shared paper, 2012 · strength 0.03
  21. Hua Chen · 1 shared paper, 2011 · strength 0.02
  22. Yingmei Zhang · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.